Sep 8, 2021 in Diagnostics, Press Releases

XPhyto Reports Successful Market Launch and Growing Demand for its 25-minute COVID-19 PCR Test COVID-ID Lab

Vancouver, Canada, and Frankfurt, Germany (September 08, 2021) – XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce the successful market launch of its 25-minute COVID-19 PCR Test COVID-ID Lab. The pilot project at the test centers in Berlin has successfully optimized the operational procedures and protocols for the rapid, efficient and reliable use of COVID-ID Lab. This technical and operational knowledge is a critical component of the product launch process and to securing sales with existing and prospective customers.

“We are extremely pleased with the pilot project results. The practical knowledge gained, from training protocols to efficient work flows, is necessary to accelerate our growing sales channels. These results confirm the effectiveness of our rapid point-of-care care diagnostic business strategy,” said Wolfgang Probst, COO and director. “In parallel to the pilot project, we are developing further approaches and services with our partners to offer modular testing and hygiene solutions for larger events, such as concerts, sporting events and conferences. Driven by the shift from antigen to PCR testing by state authorities across Germany as well as other European countries, we are convinced XPhyto can provide reliable PCR test results in only 25 minutes. Given our competitive pricing, we are in a strong position to accelerate sales growth in the near term.”

“The straight-forward testing protocol, without prior RNA extraction as part of sample preparation, and the 25-minute PCR run time enables us to process the sample directly at the collection site. With this decentralized testing model, we can yield faster results and ensure cost effectiveness even with lower testing volumes,” noted Dr. Ismail Özkanli, CEO of Beovita GmbH & Co. KG. “With the state regulations shifting from antigen to PCR testing, we see an increased demand in rapid and reliable PCR testing and, with the COVID-ID Lab, are able to offer this to our customers at a competitive price.”

XPhyto and its partners are currently developing a modular hygiene- and testing-concept for events with a large number of participants, such as concerts, sporting events, opera, theater and conferences, integrating the COVID-ID Lab test. Reliable and rapid testing on-site at the event in combination with participant registration and follow-up is essential to enable large events and ensure participants safety.

Covid-ID Lab is a rapid RT-PCR test for the qualitative detection of SARS-CoV-2 based on the reverse transcriptase polymerase chain reaction (RT-PCR) method. To perform the test, Covid-ID Lab requires only a 20-minute PCR run time without prior RNA extraction as part of sample preparation. After the RT-PCR, the SARS-CoV-2 virus is detected on a test chip within 5 minutes and if SARS-CoV-2 is present, the result can be read visually immediately.

The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 pandemic.

Media Inquiries North America
Mr. Knox Henderson
T: 604-551-2360
E: info@xphyto.com

Media Inquiries Europe
MC Services AG
Julia Hofmann, Andreas Jungfer
T: +49 89 210 228 0
E: xphyto@mc-services.eu